Pulmonx (NASDAQ:LUNG) is a medical device company focused on developing and commercializing innovative minimally invasive therapies for patients suffering from chronic obstructive pulmonary disease (COPD) and emphysema. Headquartered in Redwood City, California, Pulmonx designs products intended to improve lung function, reduce breathlessness and enhance quality of life for individuals with severe emphysema who are not candidates for traditional surgical interventions.
The company’s flagship product, the Zephyr® Endobronchial Valve, is a one-way valve that is placed via a bronchoscopic procedure to redirect air flow from diseased parts of the lung, allowing healthier regions to expand and function more efficiently. In conjunction with the Zephyr Valve, Pulmonx offers the Chartis® Pulmonary Assessment System, a diagnostic tool that helps physicians identify suitable candidates for valve therapy by measuring collateral ventilation in targeted lung lobes.
Pulmonx markets its products across multiple geographies, including the United States, Europe, Canada, Australia and Japan. The Zephyr Valve received CE Mark approval in Europe and Therapeutic Goods Administration (TGA) clearance in Australia prior to securing FDA approval in the U.S. Pulmonx works with a network of interventional pulmonologists, thoracic surgeons and specialized respiratory centers to support training, clinical evaluation and post-procedure patient care.
Since its founding in 2004, Pulmonx has advanced its therapy platform through clinical collaborations and peer-reviewed research demonstrating safety and efficacy. The company went public on the NASDAQ under the ticker symbol LUNG in 2018. Pulmonx’s leadership team, led by President and Chief Executive Officer David Zapol, brings decades of experience in medical devices, respiratory medicine and life sciences commercialization.
